Sirlander schreef op 7 januari 2020 09:27:
Capital raise likely after potential approval
Following the delay to approval of BARHEMSYS, we have reduced our forecast 2019 SG&A to reflect delayed sales activities. While Acacia has halted the hiring of sales reps, key senior sales personnel are being retained and will continue to educate and prepare the market for the potential BARHEMSYS launch in 2020. We have also reduced our forecast 2019 R&D spend (on development of BARHEMYS in chemotherapy-induced nausea and vomiting) as cost controls take effect. We forecast c £40m will need to be raised in H120 (following potential approval) to fund operations, with additional future funding dependent on sales execution.